

**(19) AUSTRALIAN PATENT OFFICE**

(54) Title  
**(20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses**

(51)<sup>6</sup> International Patent Classification(s)  
**A61K 31/593 310BMJP**  
**(2006.01) A61P 11/06**  
**A61P 1/04 20060101ALI20060**  
**(2006.01) 310BMJP**  
**A61P 3/10 A61P 17/06**  
**(2006.01) 20060101ALI20060**  
**A61P 11/06 521BMWO**  
**(2006.01) A61P 17/16**  
**A61P 17/06 20060101ALI20060**  
**(2006.01) 310BMJP**  
**A61P 17/16 A61P 19/02**  
**(2006.01) 20060101ALI20060**  
**A61P 19/02 310BMJP**  
**(2006.01) A61P 19/08**  
**A61P 19/08 20060101ALI20060**  
**(2006.01) 310BMJP**  
**A61P 19/10 A61P 19/10**  
**(2006.01) 20060101ALI20060**  
**A61P 25/00 521BMWO**  
**(2006.01) A61P 25/00**  
**A61P 29/00 20060101ALI20060**  
**(2006.01) 310BMJP**  
**A61P 35/00 A61P 29/00**  
**(2006.01) 20060101ALI20060**  
**A61P 35/02 310BMJP**  
**(2006.01) A61P 35/00**  
**A61P 37/06 20060101ALI20060**  
**(2006.01) 521BMWO**  
**C07C 49/443 A61P 35/02**  
**(2006.01) 20060101ALI20060**  
**A61K 31/593 310BMJP**  
**20060101AFI20051 A61P 37/06**  
**008BMEP 20060101ALI20060**  
**A61P 1/04 521BMWO**  
**20060101ALI20060 C07C 49/443**  
**310BMJP 20060101ALI20051**  
**A61P 3/10 008BMEP**  
**20060101ALI20060 PCT/US03/08423**

(21) Application No: **2003218267**

(22) Application Date: **2003.03.20**

(87) WIPO No: **WO03/088977**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>10/127,180</b>	<b>2002.04.22</b>	<b>US</b>

(43) Publication Date : **2003.11.03**

(43) Publication Journal Date : **2003.12.11**

(71) Applicant(s)  
**Wisconsin Alumni Research Foundation**

(72) Inventor(s)  
**Grzywacz, Pawel K.; SicinskiI, Rafal R.; Deluca, Hector F.**

(74) Agent/Attorney  
**PIZZEYS, GPO Box 1374, Brisbane, QLD, 4001**

(56) Related Art  
**US 6306844**  
**Sicinski et al. J. Med. Chem. 41, 1998, 4662-4674**  
**Castedo et al. Tetrahedron Letters, 1986, 27(13): 1523-1526**  
**Bouillon et al. Endocrine Reviews, 16(2) 1995, 200-257**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number  
WO 03/088977 A1

- (51) International Patent Classification<sup>7</sup>: **A61K 31/593**,  
A61P 17/06, 19/10, 35/00, 37/06
- (21) International Application Number: PCT/US03/08423
- (22) International Filing Date: 20 March 2003 (20.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
10/127,180 22 April 2002 (22.04.2002) US
- (71) Applicant: **WISCONSIN ALUMNI RESEARCH  
FOUNDATION** [US/US]; 614 Walnut Street, Madison,  
WI 53705 (US).
- (72) Inventors: **DELUCA, Hector, F.**; 1809 Highway Bb,  
Deerfield, WI 53531 (US). **SICINSKI, Rafal, R.**; ul.  
Waszyngtona 33 m. 150, PL-04-030 Warsaw (PL).  
**GRZYWACZ, Pawel, K.**; 218 South Bassett Street, Apt.  
104, Madison, WI 53703 (US).
- (74) Agents: **WOZNY, Thomas, M.** et al.; Andrus, Scales,  
Starke & Sawall, L.L.P. Suite 1100, 100 East Wisconsin Av-  
enue, Milwaukee, WI 53202 (US).
- (81) Designated States (*national*): AL, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
with international search report
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: (20S)-1 $\alpha$ -HYDROXY-2 $\alpha$ -METHYL AND 2 $\beta$ -METHYL-19-NOR-VITAMIN D<sub>3</sub> AND THEIR USES



(57) Abstract: This invention discloses (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> and (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.

(20S)-1 $\alpha$ -HYDROXY-2 $\alpha$ -METHYL AND 2 $\beta$ -METHYL-19-NOR-VITAMIN D<sub>3</sub>  
AND THEIR USES

BACKGROUND OF THE INVENTION

This invention relates to vitamin D compounds, and more particularly to  
5 the pro-drugs (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl and 2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> and  
their pharmaceutical uses.

The natural hormone, 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and its analog in  
ergosterol series, i.e. 1 $\alpha$ ,25-dihydroxyvitamin D<sub>2</sub> are known to be highly potent  
regulators of calcium homeostasis in animals and humans, and their activity in  
10 cellular differentiation has also been established, Ostrem et al., Proc. Natl. Acad.  
Sci. USA, 84, 2610 (1987). Many structural analogs of these metabolites have  
been prepared and tested, including 1 $\alpha$ -hydroxyvitamin D<sub>3</sub>, 1 $\alpha$ -hydroxyvitamin  
D<sub>2</sub>, various side chain homologated vitamins and fluorinated analogs. Some of  
these compounds exhibit an interesting separation of activities in cell  
15 differentiation and calcium regulation. This difference in activity may be useful in  
the treatment of a variety of diseases as renal osteodystrophy, vitamin D-resistant  
rickets, osteoporosis, psoriasis, and certain malignancies.

Recently, a new class of vitamin D analogs has been discovered, i.e. the  
so called 19-nor-vitamin D compounds, which are characterized by the  
20 replacement of the A-ring exocyclic methylene group (carbon 19), typical of the  
vitamin D system, by two hydrogen atoms. Biological testing of such 19-nor-  
analog (e.g., 1 $\alpha$ ,25-dihydroxy-19-nor-vitamin D<sub>3</sub>) revealed a selective activity  
profile with high potency in inducing cellular differentiation, and very low calcium  
mobilizing activity. Thus, these compounds are potentially useful as therapeutic  
25 agents for the treatment of malignancies, or the treatment of various skin  
disorders. Two different methods of synthesis of such 19-nor-vitamin D analogs  
have been described (Perlman et al., Tetrahedron Lett. 31, 1823 (1990); Perlman  
et al., Tetrahedron Lett. 32, 7663 (1991), and DeLuca et al., U.S. Pat. No.  
5,086,191).

In U.S. Pat. No. 4,666,634, 2 $\beta$ -hydroxy and alkoxy (e.g., ED-71) analogs of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> have been described and examined by Chugai group as potential drugs for osteoporosis and as antitumor agents. See also Okano et al., *Biochem. Biophys. Res. Commun.* **163**, 1444 (1989). Other 2-substituted (with hydroxyalkyl, e.g., ED-120, and fluoroalkyl groups) A-ring analogs of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> have also been prepared and tested (Miyamoto et al., *Chem. Pharm. Bull.* **41**, 1111 (1993); Nishii et al., *Osteoporosis Int. Suppl.* **1**, 190 (1993); Posner et al., *J. Org. Chem.* **59**, 7855 (1994), and *J. Org. Chem.* **60**, 4617 (1995)).

10 Recently, 2-substituted analogs of 1 $\alpha$ ,25-dihydroxy-19-nor-vitamin D<sub>3</sub> have also been synthesized, i.e. compounds substituted at 2-position with hydroxy or alkoxy groups (DeLuca et al., U.S. Pat. No. 5,536,713), with 2-alkyl groups (DeLuca et al U.S. Patent No. 5,945,410), and with 2-alkylidene groups (DeLuca et al U.S. Patent No. 5,843,928), which exhibit interesting and selective activity

15 profiles. All these studies indicate that binding sites in vitamin D receptors can accommodate different substituents at C-2 in the synthesized vitamin D analogs.

In a continuing effort to explore the 19-nor class of pharmacologically important vitamin D compounds, two analogs which are characterized by the presence of a methyl substituent at the carbon 2 (C-2) and the absence of a

20 hydroxyl group at carbon 25 (C-25) in the side chain have been synthesized and tested. These two analogs are characterized by a hydroxyl group at carbon 1 and a vitamin D<sub>3</sub> side chain with the methyl group attached to carbon 20 in the unnatural or epi orientation, i.e. (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl and 2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub>. These vitamin D analogs seemed interesting targets because the


25 relatively small methyl group at C-2 should not interfere with the vitamin D receptor. Moreover, molecular mechanics studies seem to indicate that such molecular modification substantially alters the conformation of the

cyclohexanediol ring A, shifting its conformational equilibrium toward the chair form with equatorially oriented methyl substituent at C-2.

# SUMMARY OF THE INVENTION

5 The present invention is directed toward the pro-drugs (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> (formula **1a** below) and (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> (formula **1b** below), their biological activity, and various pharmaceutical uses for these compounds.

Structurally these 2 $\alpha$ -methyl and 2 $\beta$ -methyl 19-nor analogs are  
 10 characterized by formula **1a** and **1b**, respectively shown below:



The above two compounds exhibit a desired, and highly advantageous, pattern of biological activity. These compounds do not bind or bind poorly to the vitamin D receptor. However, the 2 $\alpha$ -methyl compound has greater intestinal calcium transport activity, as compared to that of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and  
5 has greater ability to mobilize calcium from bone, as compared to 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>. The 2 $\beta$ -methyl compound has intestinal calcium transport activity and bone calcium mobilization activity about the same as 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>. Hence, these compounds can be characterized as having very potent calcemic activity, and are highly specific in their calcemic activity.  
10 Their activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity allows the in vivo administration of these compounds for the treatment of metabolic bone diseases where bone loss is a major concern. Because of their activity on bone, these compounds would be preferred therapeutic agents for the treatment of diseases where bone formation is desired,  
15 such as osteoporosis, especially low bone turnover osteoporosis, steroid induced osteoporosis, senile osteoporosis or postmenopausal osteoporosis, as well as osteomalacia.

The compounds of the invention have also been discovered to be especially suited for treatment and prophylaxis of human disorders which are  
20 characterized by an imbalance in the immune system, e.g. in autoimmune diseases, including multiple sclerosis, lupis, diabetes mellitus, host versus graft reaction, and rejection of organ transplants; and additionally for the treatment of inflammatory diseases, such as rheumatoid arthritis, asthma, and inflammatory bowel diseases such as celiac disease and Crohns disease. Acne, alopecia and  
25 hypertension are other conditions which may be treated with the compounds of the invention.

The above compounds are also characterized by high or significant cell differentiation activity. Thus, these compounds also provide a therapeutic agent for the treatment of psoriasis, or as an anti-cancer agent, especially against leukemia, colon cancer, breast cancer and prostate cancer. In addition, due to their relatively high cell differentiation activity, these compounds provide a therapeutic agent for the treatment of various skin conditions including wrinkles, lack of adequate dermal hydration, i.e. dry skin, lack of adequate skin firmness, i.e. slack skin, and insufficient sebum secretion. Use of these compounds thus not only results in moisturizing of skin but also improves the barrier function of skin.

The compounds may be present in a composition to treat the above-noted diseases and disorders in an amount from about 0.01 µg/gm to about 100 µg/gm of the composition, and may be administered topically, transdermally, orally or parenterally in dosages of from about 0.01 µg/day to about 100 µg/day.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph illustrating the relative activity of (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D<sub>3</sub>, (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D<sub>3</sub>, and 1α,25-dihydroxyvitamin D<sub>3</sub> to compete for binding of [<sup>3</sup>H]-1,25-(OH)<sub>2</sub>-D<sub>3</sub> to the vitamin D pig intestinal nuclear receptor; and


Figure 2 is a graph illustrating the percent HL-60 cell differentiation as a function of the concentration of (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D<sub>3</sub>, (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D<sub>3</sub>, and of 1α,25-dihydroxyvitamin D<sub>3</sub>.

#### DETAILED DESCRIPTION OF THE INVENTION

(20S)-1α-Hydroxy-2α-methyl-19-nor-vitamin D<sub>3</sub> and (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D<sub>3</sub> were synthesized and tested. Structurally, these 19-nor analogs are characterized by the formula **Ia** and **Ib**, respectively, previously illustrated herein.


The preparation of (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl- and (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> having structures **Ia** and **Ib** can be accomplished by a common general method, i.e. the condensation of a bicyclic Windaus-Grundmann type ketone **II** with the allylic phosphine oxide **III** to the corresponding

5 2-methylene-19-nor-vitamin D analog **IV** followed by deprotection of hydroxyls at C-1 and C-3 in the latter compound; and then followed by a selective reduction of the exomethylene group at C-2 in compound **V** to provide the 2 $\alpha$ -methyl isomer (**Ia**) and 2 $\beta$ -methyl isomer (**Ib**):



10





In the structures III and IV groups  $Y_1$  and  $Y_2$  are hydroxy-protecting groups, preferably  $t\text{BuMe}_2\text{Si}$  groups, it being also understood that any functionalities that might be sensitive, or that interfere with the condensation reaction, be suitably protected as is well-known in the art. The process shown above represents an application of the convergent synthesis concept, which has been applied effectively for the preparation of vitamin D compounds [e.g. Lythgoe et al., J. Chem. Soc. Perkin Trans. I, 590 (1978); Lythgoe, Chem. Soc. Rev. 9, 449 (1983); Toh et al., J. Org. Chem. 48, 1414 (1983); Baggiolini et al., J. Org. Chem. 51, 3098 (1986); Sardina et al., J. Org. Chem. 51, 1264 (1986); J. Org. Chem. 51, 1269 (1986); DeLuca et al., U.S. Pat. No. 5,086,191; DeLuca et al., U.S. Pat. No. 5,536,713].

A hydrindanone of the structure II is a new compound that can be prepared from commercial vitamin  $D_2$  by modification of known methods. Thus, the starting alcohol 1 was prepared from commercial vitamin  $D_2$  in 3 steps (Scheme 1). The resulting C-22 alcohol 1 was oxidized to the aldehyde 2, which then was equilibrated at C-20. The mixture of (20R)- and (20S)-aldehydes was reduced and (20R)-alcohol 3 was isolated by chromatography. This, in turn, was

tosylated and the tosylate **4** coupled with the Grignard reagent **5** in the presence of dilithium tetrachlorocuprate. The obtained hydrindanol **6** was oxidized to the new (20S)-Grundmann ketone analog **II**.

For the preparation of the required phosphine oxides of general structure **III**, a new synthetic route has been developed starting from a methyl quinate derivative which is easily obtained from commercial (1R,3R,4S,5R)-(-)-quinic acid as described by Perlman et al., *Tetrahedron Lett.* **32**, 7663 (1991) and DeLuca et al., U.S. Pat. No. 5,086,191.

The final step of the process is the selective homogeneous catalytic hydrogenation of the exomethylene unit at carbon 2 in the vitamin **V** performed efficiently in the presence of tris(triphenylphosphine)rhodium(I) chloride [Wilkinson's catalyst,  $(\text{Ph}_3\text{P})_3\text{RhCl}$ ]. Such reduction conditions allowed to reduce only  $\text{C}(2)=\text{CH}_2$  unit leaving  $\text{C}(5)-\text{C}(8)$  butadiene moiety unaffected. The isolated material is an epimeric mixture (ca. 1:1) of 2-methyl-19-nor-vitamins **Ia** and **Ib** differing in configuration at C-2. The mixture can be used without separation or, if desired, the individual  $2\alpha$ - and  $2\beta$ -isomers can be separated by an efficient HPLC system.

The overall process of the synthesis of compounds **Ia** and **Ib** is illustrated and described more completely in U.S. Patent 5,945,410 entitled "2-Alkyl-19-Nor-Vitamin D Compounds" the specification of which is specifically incorporated herein by reference.

Specifically, the preparation of hydrindanone **II** is described hereinafter and illustrated in Scheme I. The final steps of the convergent synthesis, i.e. the coupling of this compound with phosphine oxide **7** followed by hydroxyl

deprotection in the vitamin D compound **8** and reduction/hydrogenation of the exomethylene unit in 2-methylene-19-nor-vitamin D compound **V** is also hereinafter described and illustrated in Scheme 2.

**Preparation of (20S)-de-A,B-8 $\beta$ -benzoyloxy-20-(hydroxymethyl)pregnane (1).**

The starting alcohol **1** was prepared from commercial vitamin D<sub>2</sub> in 70% yield, according to the procedure published by J. C. Hanekamp, R. B. Rookhuizen, H. J. T. Bos, L. Brandsma *Tetrahedron*, **1992**, *48*, 9283-9294.

Ozone was passed through a solution of vitamin D<sub>2</sub> (3 g, 7.6 mmol) in methanol (250 mL) and pyridine (2.44 g, 2.5 mL, 31 mmol) for 50 min at -78 °C. The reaction mixture was then flushed with an oxygen for 15 min to remove the residual ozone and the solution was treated with NaBH<sub>4</sub> (0.75 g, 20 mmol). After 20 min the second portion of NaBH<sub>4</sub> (0.75 g, 20 mmol) was added and the mixture was allowed to warm to room temperature. The third portion of NaBH<sub>4</sub> (0.75 g, 20 mmol) was then added and the reaction mixture was stirred for 18 h. The reaction was quenched with water (40 mL) and the solution was concentrated under reduced pressure. The residue was extracted with ethyl acetate (3  $\times$  80 mL) and the combined organic phase was washed with 1M aq. HCl, saturated aq. NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure. The residue was chromatographed on silica gel with hexane/ethyl acetate (75:25) to give (20S)-de-A,B-20-(hydroxymethyl)pregnan-8 $\beta$ -ol (1.21 g, 75% yield) as white crystals.

Benzoyl chloride (2.4 g, 2 mL, 17 mmol) was added to a solution of the 8 $\beta$ ,20-diol (1.2 g, 5.7 mmol) and DMAP (30 mg, 0.2 mmol) in anhydrous pyridine (20 mL) at 0 °C. The reaction mixture was stirred at 4 °C for 24 h, diluted with methylene chloride (100 mL), washed with 5% aq. HCl, water, saturated aq. NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure. The residue (3.39 g) was treated with solution of KOH (1g, 15.5 mmol) in anhydrous ethanol (30 mL) at room temperature. After stirring of the reaction mixture for 3 h, ice and 5% aq. HCl were added until pH=6. The solution was extracted with ethyl acetate (3  $\times$  50 mL) and the combined organic phase was washed with saturated aq. NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure. The residue was chromatographed on silica gel with hexane/ethyl acetate (75:25) to give the alcohol **1** (1.67 g, 93% yield) as a colorless oil: [ $\alpha$ ]<sub>D</sub> +56.0 (*c* 0.48, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> + TMS)  $\delta$  8.08-8.02 (2H, m, *o*-H<sub>Bz</sub>), 7.59-7.53 (1H, m, *p*-H<sub>Bz</sub>), 7.50-7.40 (2H, m, *m*-H<sub>Bz</sub>), 5.42 (1H, d, *J* = 2.4 Hz, 8 $\alpha$ -H), 3.65 (1H, dd, *J* = 10.5, 3.2 Hz, 22-H), 3.39 (1H, dd, *J* = 10.5, 6.8 Hz, 22-H), 1.08 (3H, d, *J* = 5.3 Hz, 21-H<sub>3</sub>), 1.07 (3H, s, 18-H<sub>3</sub>); <sup>13</sup>C NMR (125 MHz)  $\delta$  166.70 (s, C=O), 132.93 (d, *p*-C<sub>Bz</sub>), 131.04 (s, *i*-C<sub>Bz</sub>),

129.75 (d, *o*-C<sub>Bz</sub>), 128.57 (d, *m*-C<sub>Bz</sub>), 72.27 (d, C-8), 67.95 (t, C-22), 52.96 (d), 51.60 (d), 42.15 (s, C-13), 39.98 (t), 38.61 (d), 30.73 (t), 26.81 (t), 22.91 (t), 18.20 (t), 16.87 (q, C-21), 13.81 (q, C-18); MS (EI) *m/z* 316 (5, M<sup>+</sup>), 301 (3, M<sup>+</sup> - Me), 299 (1, M<sup>+</sup> - OH), 298 (2, M<sup>+</sup> - H<sub>2</sub>O), 285 (10, M<sup>+</sup> - CH<sub>2</sub>OH), 257 (6), 230 (9), 194 (80), 135 (84), 105 (100); exact mass calculated for C<sub>20</sub>H<sub>28</sub>O<sub>3</sub> 316.2038, found 316.2019.

#### Preparation of (20*S*)-de-A,B-8β-benzoyloxy-20-formylpregnane (2).

A mixture of alcohol 1 (1.63 g, 5.2 mmol), pyridinium dichromate (6.05 g, 16.1 mmol) and pyridinium *p*-toluenesulfonate (100 mg, 0.4 mmol) in anhydrous methylene chloride (30 mL) was stirred at room temperature for 12 h. The resulting suspension was filtered through a short layer of Celite. The adsorbent was washed with ether, solvents were removed under reduced pressure and a residue was purified by column chromatography on silica gel with hexane/ethyl acetate (90:10) to give the aldehyde 2 (1.36 g, 83% yield) as an oil: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>+TMS) δ 9.60 (1H, d, J = 3.1 Hz, CHO), 8.05 (2H, m, *o*-H<sub>Bz</sub>), 7.57 (1H, m, *p*-H<sub>Bz</sub>), 7.45 (2H, m, *m*-H<sub>Bz</sub>), 5.44 (1H, s, 8α-H), 2.39 (1H, m, 20-H), 2.03 (2H, dm, J = 11.5 Hz), 1.15 (3H, d, J = 6.9 Hz, 21-H<sub>3</sub>), 1.10 (3H, s, 18-H<sub>3</sub>); MS (EI) *m/z* 314 (1, M<sup>+</sup>), 299 (0.5, M<sup>+</sup> - Me), 286 (1, M<sup>+</sup> - CO), 285 (5, M<sup>+</sup> - CHO), 257 (1, M<sup>+</sup> - C<sub>3</sub>H<sub>5</sub>O), 209 (10, M<sup>+</sup> - PhCO), 192 (38), 134 (60), 105 (100), 77 (50); exact mass calculated for C<sub>20</sub>H<sub>26</sub>O<sub>3</sub> 314.1882, found 314.1887.

#### Preparation of (20*R*)-de-A,B-8β-benzoyloxy-20-(hydroxymethyl)pregnane (3).

The aldehyde 2 (1.36 g, 4.3 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and a 40% aq. n-Bu<sub>4</sub>NOH solution (5.6 mL, 5.57 g, 8.6 mmol) was added. The resulting mixture was stirred at room temperature for 16 h, diluted with methylene chloride (30 mL), washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure. A residue was chromatographed on silica gel with hexane/ethyl acetate (95:5) to afford a mixture of aldehyde 2 and its 20-epimer (730 mg, 53% yield) in ca. 1:1.7 ratio (by <sup>1</sup>H NMR).

This mixture of aldehydes (730 mg, 2.3 mmol) was dissolved in THF (5 mL) and NaBH<sub>4</sub> (175 mg, 4.6 mmol) was added, followed by a dropwise addition of ethanol (5 mL). The reaction mixture was stirred at room temperature for 30 min and it was quenched with a saturated aq. NH<sub>4</sub>Cl solution. The mixture was extracted with ether (3 × 30 mL) and the combined organic phase was washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>) and

concentrated under reduced pressure. The residue was chromatographed on silica gel with hexane/ethyl acetate (95:5 → 80:20) to give the desired, pure (20*R*)-alcohol 3 (366 mg, 52% yield) as an oil and a mixture of 3 and its 20-epimer 1 (325 mg, 45% yield) in ca. 1:4 ratio (by <sup>1</sup>H NMR).

3: [ $\alpha$ ]<sub>D</sub> +43.0 (c 0.54, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> + TMS)  $\delta$  8.10-8.00 (2H, m, *o*-H<sub>Bz</sub>), 7.60-7.53 (1H, m, *p*-H<sub>Bz</sub>), 7.48-7.41 (2H, m, *m*-H<sub>Bz</sub>), 5.42 (1H, br s, 8 $\alpha$ -H), 3.75 (1H, dd, J = 10.6, 3.5 Hz, 22-H), 3.48 (1H, dd, J = 10.6, 7.0 Hz, 22-H), 1.069 (3H, s, 18-H<sub>3</sub>), 0.973 (3H, d, J = 6.7 Hz, 21-H<sub>3</sub>); <sup>13</sup>C NMR (125 MHz)  $\delta$  166.70 (s, C=O), 132.94 (d, *p*-C<sub>Bz</sub>), 131.05 (s, *i*-C<sub>Bz</sub>), 129.76 (d, *o*-C<sub>Bz</sub>), 128.59 (d, *m*-C<sub>Bz</sub>), 72.28 (d, C-8), 66.95 (t, C-22), 52.94 (d), 51.77 (d), 41.96 (s, C-13), 39.56 (t), 37.78 (d), 30.75 (t), 26.67 (t), 22.71 (t), 18.25 (t), 16.76 (q, C-21), 14.14 (q, C-18); MS (EI) *m/z* 316 (16, M<sup>+</sup>), 301 (5, M<sup>+</sup> - Me), 299 (2, M<sup>+</sup> - OH), 298 (3, M<sup>+</sup> - H<sub>2</sub>O), 285 (9, M<sup>+</sup> - CH<sub>2</sub>OH), 257 (5), 242 (11), 230 (8), 194 (60), 147 (71), 105 (100); exact mass calculated for C<sub>20</sub>H<sub>28</sub>O<sub>3</sub> 316.2038, found 316.2050.

**Preparation of (20*R*)-de-A,B-8-benzoyloxy-20-[(*p*-toluenesulfonyl)oxymethyl]pregnane (4).**

To a stirred solution of the alcohol 3 (393 mg, 1.24 mmol), DMAP (10 mg, 0.08 mmol) and Et<sub>3</sub>N (0.7 mL, 0.51 g, 5.04 mmol) in anhydrous methylene chloride (10 mL) was added *p*-toluenesulfonyl chloride (320 mg, 1.68 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature (4 h) and stirring was continued for additional 22 h. Methylene chloride (60 mL) was added and the mixture was washed with a saturated aq. NaHCO<sub>3</sub> solution, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure. A residue was chromatographed on silica gel with hexane/ethyl acetate (95:5) to afford a tosylate 4 (533 mg, 91% yield) as a colorless oil: [ $\alpha$ ]<sub>D</sub> = +15.0 (c 0.54, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> + TMS)  $\delta$  8.02 (2H, m, *o*-H<sub>Bz</sub>), 7.80 (2H, d, J = 8.2 Hz, *o*-H<sub>TS</sub>), 7.55 (1H, m, *p*-H<sub>Bz</sub>), 7.44 (2H, m, *m*-H<sub>Bz</sub>), 7.35 (2H, d, J = 8.2 Hz, *m*-H<sub>TS</sub>), 5.39 (1H, br s, 8 $\alpha$ -H), 4.15 (1H, dd, J = 9.4, 3.4 Hz, 22-H), 3.83 (1H, dd, J = 9.4, 7.1 Hz, 22-H), 2.457 (3H, s, Me<sub>TS</sub>), 1.98 (1H, m), 0.978 (3H, s, 18-H<sub>3</sub>), 0.898 (3H, d, J = 6.6 Hz, 21-H<sub>3</sub>); <sup>13</sup>C NMR (125 MHz)  $\delta$  166.60 (s, C=O), 144.87 (s, *p*-C<sub>TS</sub>), 133.35 (s, *i*-C<sub>TS</sub>), 132.98 (d, *p*-C<sub>Bz</sub>), 130.94 (s, *i*-C<sub>Bz</sub>), 129.97 (d, *m*-C<sub>TS</sub>), 129.72 (d, *o*-C<sub>Bz</sub>), 128.58 (d, *m*-C<sub>Bz</sub>), 128.13 (d, *o*-C<sub>TS</sub>), 74.21 (t, C-22), 72.03 (d, C-8), 52.44 (d), 51.52 (d), 41.82 (s, C-13), 39.30 (t), 35.00 (d), 30.57 (t), 26.56 (t), 22.54 (t), 21.85 (q, Me<sub>TS</sub>), 18.12 (t), 16.85 (q, C-21), 14.09 (q, C-

18); MS (EI)  $m/z$  470 (1,  $M^+$ ), 365 (33,  $M^+ - \text{PhCO}$ ), 348 (64,  $M^+ - \text{PhCOOH}$ ), 193 (52), 176 (71), 134 (72), 105 (100); exact mass calculated for  $\text{C}_{27}\text{H}_{34}\text{O}_5\text{S}$  470.2127, found 470.2091.

**Preparation of (20S)-de-A,B-cholestan-8 $\beta$ -ol (6).**

Magnesium turnings (1.32 g, 55 mmol), 1-chloro-3-methylbutane (3.3 mL, 2.9 g, 27.2 mmol) and iodine (2 crystals) were refluxed in anhydrous THF (18 mL) for 10 h. The solution of the formed Grignard reagent 5 was cooled to  $-78^\circ\text{C}$  and added dropwise *via* cannula to a solution of the tosylate 4 (348 mg, 0.74 mmol) in anhydrous THF (5 mL) at  $-78^\circ\text{C}$ . Then 6 mL of the solution of  $\text{Li}_2\text{CuCl}_4$  [prepared by dissolving of a dry LiCl (232 mg, 5.46 mmol) and dry  $\text{CuCl}_2$  (368 mg, 2.75 mmol) in anhydrous THF (27 mL)] was added dropwise *via* cannula to the reaction mixture at  $-78^\circ\text{C}$ . The cooling bath was removed and the mixture was stirred at room temperature for 20 h and then poured into 1M aq.  $\text{H}_2\text{SO}_4$  solution (25 mL) containing ice (ca. 100 g). The mixture was extracted with methylene chloride ( $3 \times 50$  mL) and the combined organic layers were washed with saturated aq.  $\text{NH}_4\text{Cl}$ , saturated aq.  $\text{NaHCO}_3$ , dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated under reduced pressure. The residue was chromatographed on silica gel with chloroform to give alcohol 6 (149 mg, 76% yield) as a colorless oil:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3 + \text{TMS}$ )  $\delta$  4.07 (1H, d,  $J = 2.2$  Hz, 8 $\alpha$ -H), 1.98 (1H, dm,  $J = 13.1$  Hz), 0.93 (3H, s, 18- $\text{H}_3$ ), 0.86 (6H, d,  $J = 6.6$  Hz, 26- and 27- $\text{H}_3$ ), 0.81 (3H, d,  $J = 6.6$  Hz, 21- $\text{H}_3$ );  $^{13}\text{C}$  NMR (125 MHz)  $\delta$  69.41 (d, C-8), 56.27 (d), 52.62 (d), 41.84 (s, C-13), 40.28 (t), 39.38 (t), 35.40 (t), 34.83 (d), 33.51 (t), 28.03 (d), 27.10 (t), 23.93 (t), 22.72 (q, C-26/27), 22.63 (q, C-26/27), 22.40 (t), 18.53 (q, C-21), 17.47 (t), 13.73 (q, C-18); MS (EI)  $m/z$  266 (7,  $M^+$ ), 251 (6,  $M^+ - \text{Me}$ ), 248 (2,  $M^+ - \text{H}_2\text{O}$ ), 233 (4,  $M^+ - \text{Me} - \text{H}_2\text{O}$ ), 163 (6), 152 (11), 135 (38), 111 (100); exact mass calculated for  $\text{C}_{18}\text{H}_{34}\text{O}$  266.2610, found 266.2601.

**Preparation of (20S)-de-A,B-cholestan-8-one (II).**

Pyridinium dichromate (90 mg, 239  $\mu\text{mol}$ ) was added to a solution of the alcohol 6 (15 mg, 56  $\mu\text{mol}$ ) and pyridinium p-toluenesulfonate (2 mg, 8  $\mu\text{mol}$ ) in anhydrous methylene chloride (6 mL). The resulting suspension was stirred at room temperature for 3.5 h. The reaction mixture was filtered through a Waters silica Sep-Pak cartridge (2 g) that was further washed with  $\text{CHCl}_3$ . After removal of solvents ketone II (13 mg, 88% yield) was obtained as a colorless oil:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3 + \text{TMS}$ )  $\delta$  2.46 (1H,

dd,  $J = 11.5, 7.6$  Hz), 0.89 (6H, d,  $J = 6.6$  Hz, 26- and 27- $H_3$ ), 0.87 (3H, d,  $J = 6.1$  Hz, 21- $H_3$ ), 0.65 (3H, s, 18- $H_3$ ); MS (EI)  $m/z$  264 (41,  $M^+$ ), 249 (37,  $M^+ - Me$ ), 246 (3,  $M^+ - H_2O$ ), 231 (3,  $M^+ - Me - H_2O$ ), 221 (50,  $M^+ - C_3H_7$ ), 152 (34), 125 (100), 111 (69); exact mass calculated for  $C_{18}H_{32}O$  264.2453, found 264.2454.

#### Preparation of (20S)-1 $\alpha$ -hydroxy-2-methylene-19-norvitamin D<sub>3</sub> (V).

To a solution of phosphine oxide 7 (34 mg, 58  $\mu$ mol) in anhydrous THF (450  $\mu$ L) at -20 °C was slowly added PhLi (1.7 M in cyclohexane-ether, 75  $\mu$ L, 128  $\mu$ mol) under argon with stirring. The solution turned deep orange. After 30 min the mixture was cooled to -78 °C and a precooled (-78 °C) solution of ketone II (12 mg, 45  $\mu$ mol) in anhydrous THF (200 + 100  $\mu$ L) was slowly added. The mixture was stirred under argon at -78 °C for 3 h and at 0 °C for 18 h. Ethyl acetate was added, and the organic phase was washed with brine, dried ( $Na_2SO_4$ ) and evaporated. The residue was dissolved in hexane and applied on a Waters silica Sep-Pak cartridge (2 g). The cartridge was washed with hexane and hexane/ethyl acetate (99.5:0.5) to give 19-norvitamin derivative 8 (12 mg). The Sep-Pak was then washed with hexane/ethyl acetate (96:4) to recover the unchanged C,D-ring ketone II (7 mg), and with ethyl acetate to recover diphenylphosphine oxide 7 (19 mg). The protected vitamin 8 was further purified by HPLC (10  $\times$  250 mm Zorbax-Silica column, 4 mL/min) using hexane/2-propanol (99.9:0.1) solvent system. Pure compound 8 (10 mg, 36% yield) was eluted at  $R_V = 15$  mL as a colorless oil: UV (in hexane)  $\lambda_{max}$  262.5, 252.5, 243.5 nm;  $^1H$  NMR (500 MHz,  $CDCl_3$ )  $\delta$  6.21 and 5.82 (1H and 1H, each d,  $J = 11.1$  Hz, 6- and 7-H), 4.95 and 4.90 (1H and 1H, each s, =CH<sub>2</sub>), 4.41 (2H, m, 1 $\beta$ - and 3 $\alpha$ -H), 2.80 (1H, dd,  $J = 11.9, 3.5$  Hz, 9 $\beta$ -H), 2.49 (1H, dd,  $J = 13.2, 6.0$  Hz, 10 $\alpha$ -H), 2.44 (1H, dd,  $J = 12.7, 4.6$  Hz, 4 $\alpha$ -H), 2.32 (1H, dd,  $J = 13.2, 3.1$  Hz, 10 $\beta$ -H), 2.16 (1H, dd,  $J = 12.7, 8.2$  Hz, 4 $\beta$ -H), 1.98 (2H, m), 1.84 (1H, m), 0.876 (9H, s, Si-*t*-Bu), 0.851 (6H, d,  $J = 6.0$  Hz, 26- and 27- $H_3$ ), 0.845 (9H, s, Si-*t*-Bu), 0.820 (3H, d,  $J = 6.5$  Hz, 21- $H_3$ ), 0.521 (3H, s, 18- $H_3$ ), 0.060, 0.046, 0.029 and 0.006 (each 3H, each s, 4  $\times$  Si-CH<sub>3</sub>); MS (EI)  $m/z$  628 (3,  $M^+$ ), 613 (1,  $M^+ - Me$ ), 571 (3,  $M^+ - t$ -Bu), 496 (63,  $M^+ - t$ -BuMe<sub>2</sub>SiOH), 383 (4,  $M^+ - t$ -BuMe<sub>2</sub>SiOH - C<sub>8</sub>H<sub>17</sub>), 366 (21), 234 (20), 129 (41), 75 (100); exact mass calculated for C<sub>39</sub>H<sub>72</sub>O<sub>2</sub>Si<sub>2</sub> 628.5071, found 628.5068.

Protected vitamin 8 (10 mg, 16  $\mu$ mol) was dissolved in anhydrous THF (3 mL) and a solution of tetrabutylammonium fluoride (1 M in THF, 160  $\mu$ L, 160  $\mu$ mol) was added, followed by freshly activated molecular sieves 4A (300 mg). The mixture was stirred under argon at room temperature for 2 h, then diluted with 2 mL of hexane/ethyl acetate (6:4) and applied on a Waters silica Sep-Pak cartridge (2 g). Elution with the same

solvent system gave the crude product **V** that was further purified by HPLC (10 × 250 mm Zorbax-Silica column, 4 mL/min) using hexane/2-propanol (9:1) solvent system. Analytically pure 2-methylene-19-norvitamin **V** (3.3 mg, 52% yield) was collected at  $R_V = 32$  mL as a colorless oil: UV (in EtOH)  $\lambda_{\max}$  261.5, 251.5, 243.5 nm;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3 + \text{TMS}$ )  $\delta$  6.36 and 5.88 (1H and 1H, each d,  $J = 11.3$  Hz, 6- and 7-H), 5.11 and 5.09 (each 1H, each s,  $=\text{CH}_2$ ), 4.47 (2H, m, 1 $\beta$ - and 3 $\alpha$ -H), 2.85 (1H, dd,  $J = 13.4$ , 4.6 Hz, 10 $\beta$ -H), 2.81 (1H, br d,  $J = 13.9$  Hz, 9 $\beta$ -H), 2.58 (1H, dd,  $J = 13.2$ , 3.7 Hz, 4 $\alpha$ -H), 2.33 (1H, dd,  $J = 13.2$ , 6.1 Hz, 4 $\beta$ -H), 2.29 (1H, dd,  $J = 13.4$ , 8.4 Hz, 10 $\alpha$ -H), 1.99 (2H, m), 1.86 (1H, m), 0.867 (6H, d,  $J = 6.6$  Hz, 26- and 27- $\text{H}_3$ ), 0.839 (3H, d,  $J = 6.5$  Hz, 21- $\text{H}_3$ ), 0.547 (3H, s, 18- $\text{H}_3$ ); MS (EI)  $m/z$  400 (100,  $\text{M}^+$ ), 385 (5,  $\text{M}^+ - \text{Me}$ ), 382 (16,  $\text{M}^+ - \text{H}_2\text{O}$ ), 367 (6,  $\text{M}^+ - \text{Me} - \text{H}_2\text{O}$ ), 349 (3,  $\text{M}^+ - \text{Me} - 2\text{H}_2\text{O}$ ), 315 (46), 287 (56,  $\text{M}^+ - \text{C}_8\text{H}_{17}$ ), 269 (52), 247 (42); exact mass calculated for  $\text{C}_{27}\text{H}_{44}\text{O}_2$  400.3341, found 400.3346.

**Preparation of (20*S*)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-norvitamin **D**<sub>3</sub> (**Ia**) and (20*S*)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-norvitamin **D**<sub>3</sub> (**Ib**).**


Tris(triphenylphosphine)rhodium (I) chloride (3.5 mg, 3.8  $\mu\text{mol}$ ) was added to dry benzene (2.5 mL) presaturated with hydrogen. The mixture was stirred at room temperature until a homogeneous solution was formed (ca. 45 min). A solution of vitamin **V** (1.8 mg, 4.5  $\mu\text{mol}$ ) in dry benzene (400+400  $\mu\text{L}$ ) was then added and the reaction was allowed to proceed under a continuous stream of hydrogen for 3 h. Benzene was removed under vacuum, the residue was redissolved in hexane/ethyl acetate (1:1) and applied on a Waters silica Sep-Pak cartridge (2 g). A mixture of 2-methyl vitamins was eluted with the same solvent system. The compounds were further purified by HPLC (10 × 250 mm Zorbax-Silica column, 4 mL/min) using hexane/2-propanol (9:1) solvent system. The mixture of 2-methyl-19-norvitamins **Ia** and **Ib** gave a single peak at  $R_V = 34$  mL. Separation of both epimers was achieved by reversed-phase HPLC (10 × 250 mm Chromagabond C18 column, 3 mL/min) using methanol/water (9:1) solvent system. 2 $\beta$ -Methyl vitamin **Ib** (280  $\mu\text{g}$ , 15% yield) was collected at  $R_V = 47$  mL and its 2 $\alpha$ -epimer **Ia** (382  $\mu\text{g}$ , 21% yield) at  $R_V = 51$  mL.

**Ia**: UV (in EtOH)  $\lambda_{\max}$  260.5, 250.5, 242.5 nm;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3 + \text{TMS}$ )  $\delta$  6.37 and 5.82 (1H and 1H, each d,  $J = 11.1$  Hz, 6- and 7-H), 3.96 (1H, m,  $w/2 = 14$  Hz, 1 $\beta$ -H), 3.61 (1H, m,  $w/2 = 20$  Hz, 3 $\alpha$ -H), 2.80 (2H, br m, 9 $\beta$ - and 10 $\alpha$ -H), 2.60 (1H, dd,  $J = 13.0$ , 4.5 Hz, 4 $\alpha$ -H), 2.22 (1H, br d,  $J = 12.8$  Hz, 10 $\beta$ -H), 2.13 (1H, ~ t,  $J = 13.0$  Hz, 4 $\beta$ -H), 1.133 (3H, d,  $J = 6.8$  Hz, 2 $\alpha$ - $\text{CH}_3$ ), 0.866 (6H, d,  $J = 6.6$  Hz, 26- and 27- $\text{H}_3$ ),




0.833 (3H, d,  $J = 6.4$  Hz, 21-H<sub>3</sub>), 0.530 (3H, s, 18-H<sub>3</sub>); MS (EI)  $m/z$  402 (100, M<sup>+</sup>), 387 (4, M<sup>+</sup> - Me), 384 (7, M<sup>+</sup> - H<sub>2</sub>O), 369 (3, M<sup>+</sup> - Me - H<sub>2</sub>O), 317 (24), 289 (60, M<sup>+</sup> - C<sub>8</sub>H<sub>17</sub>), 271 (33), 259 (40), 247 (63); exact mass calculated for C<sub>27</sub>H<sub>46</sub>O<sub>2</sub> 402.3498, found 402.3496.

**Ib:** UV (in EtOH)  $\lambda_{\max}$  260.5, 250.0, 242.0 nm; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>+TMS)  $\delta$  6.26 and 5.87 (1H and 1H, each d,  $J = 11.3$  Hz, 6-H and 7-H), 3.90 (1H, m,  $w/2 = 14$  Hz, 3 $\alpha$ -H), 3.50 (1H, m,  $w/2 = 26$  Hz, 1 $\beta$ -H), 3.08 (1H, dd,  $J = 12.6, 4.3$  Hz, 10 $\beta$ -H), 2.80 (1H, dd,  $J = 12.5, 3.8$  Hz, 9 $\beta$ -H), 2.43 (1H, br d,  $J = \text{ca. } 14$  Hz, 4 $\alpha$ -H), 2.34 (1H, dd,  $J = 13.9, 3.0$  Hz, 4 $\beta$ -H), 1.143 (3H, d,  $J = 6.8$  Hz, 2 $\beta$ -CH<sub>3</sub>) 0.867 (6H, d,  $J = 6.6$  Hz, 26- and 27-H<sub>3</sub>), 0.839 (3H, d,  $J = 6.5$  Hz, 21-H<sub>3</sub>), 0.543 (3H, s, 18-H<sub>3</sub>); MS (EI)  $m/z$  402 (100, M<sup>+</sup>), 387 (8, M<sup>+</sup> - Me), 384 (8, M<sup>+</sup> - H<sub>2</sub>O), 369 (5, M<sup>+</sup> - Me - H<sub>2</sub>O), 317 (42), 289 (88, M<sup>+</sup> - C<sub>8</sub>H<sub>17</sub>), 271 (52), 259 (55), 247 (66); exact mass calculated for C<sub>27</sub>H<sub>46</sub>O<sub>2</sub> 402.3498, found 402.3486.



Scheme 2



BIOLOGICAL ACTIVITY OF (20S)-1 $\alpha$ -HYDROXY-2 $\alpha$ -METHYL AND 2 $\beta$ -  
METHYL-19-NOR-VITAMIN D<sub>3</sub>

The 2 $\beta$ -methyl-(20S)-1 $\alpha$ -hydroxyvitamin D<sub>3</sub> does not bind to the vitamin D receptor, while the 2 $\alpha$ -methyl-(20S)-1 $\alpha$ -hydroxyvitamin D<sub>3</sub> binds the receptor but  
5 at a 100-fold less affinity than 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> (1,25-(OH)<sub>2</sub>D<sub>3</sub>) (Figure 1). The absence of a 25-hydroxyl group in these compounds is largely responsible (see Eisman, J.A. and H.F. DeLuca, *Steroids* **30**, 245-257, 1977) for this diminished activity. Importantly, the 2 $\alpha$ -methyl derivative is superior to the 2 $\beta$ -methyl analog in binding to the receptor.

10 Surprisingly, Figure 2 illustrates (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> is almost as potent as 1,25-(OH)<sub>2</sub>D<sub>3</sub> on HL-60 differentiation, making it an excellent candidate for the treatment of psoriasis and cancer, especially against leukemia, colon cancer, breast cancer and prostate cancer. In addition, due to its relatively high cell differentiation activity, this compound provides a  
15 therapeutic agent for the treatment of various skin conditions including wrinkles, lack of adequate dermal hydration, i.e. dry skin, lack of adequate skin firmness, i.e. slack skin, and insufficient sebum secretion. Use of this compound thus not only results in moisturizing of skin but also improves the barrier function of skin. The 2 $\beta$  derivative is 100 times less active than 1,25(OH)<sub>2</sub>D<sub>3</sub> making it less  
20 effective in these areas.

The data in Table 1 show that (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> has high activity relative to that of 1,25-(OH)<sub>2</sub>D<sub>3</sub>, the natural hormone, in stimulating intestinal calcium transport. Also, (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> has significant activity in stimulating intestinal calcium transport,  
25 and its activity is about the same as 1,25-(OH)<sub>2</sub>D<sub>3</sub>.

The data in Table 1 also demonstrate that (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> has higher bone calcium mobilization activity, as compared to 1,25-(OH)<sub>2</sub>D<sub>3</sub>. Also, (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> has

significant bone calcium mobilization activity, and its activity is about the same as 1,25-(OH)<sub>2</sub>D<sub>3</sub>.

A very important feature of these analogs is that they bind poorly or not at all to the vitamin D receptor, while having biological activity either higher than or equal to 1,25-(OH)<sub>2</sub>D<sub>3</sub>. This suggests that these analogs are pro drugs. That is, they are probably activated *in vivo* by being 25-hydroxylated. Once 25-hydroxylated, they are then able to bind the vitamin D receptor and provide activity. These results suggest that these compounds might be preferable to the final drug in that they are slowly activated within the body providing a more controlled and prolonged activity.

The data in Table 1 thus illustrate that (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> may be characterized as having significant and very potent calcemic activity which is greater than 1,25-(OH)<sub>2</sub>D<sub>3</sub>, and that (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> also has significant and very potent calcemic activity that is about the same as 1,25-(OH)<sub>2</sub>D<sub>3</sub>.

Competitive binding of the analogs to the porcine intestinal receptor was carried out by the method described by Dame et al. (Biochemistry 25, 4523-4534, 1986).

The differentiation of HL-60 promyelocytic into monocytes was determined as described by Ostrem et al. (J. Biol. Chem. 262, 14164-14171, 1987).

Intestinal calcium transport was determined as described by Perlman et al. (Biochemistry 29, 190-196, 1990).

#### INTERPRETATION OF DATA

The *in vivo* tests to determine serum calcium of rats on a low calcium diet provides an insight to osteoblastic or bone activity of (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> and (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub>. The data in Table 1 show that (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> is

significantly more potent than  $1,25(\text{OH})_2\text{D}_3$  in raising calcium in the plasma via the stimulation of the osteoblasts. At the same time, the activity of (20S)- $1\alpha$ -hydroxy- $2\alpha$ -methyl-19-nor-vitamin  $\text{D}_3$  on intestinal calcium transport is also significantly greater than that of  $1,25(\text{OH})_2\text{D}_3$  (Table 1). Therefore, these data show (20S)- $1\alpha$ -hydroxy- $2\alpha$ -methyl-19-nor-vitamin  $\text{D}_3$  to have significant and very potent activity on bone which is higher than  $1,25(\text{OH})_2\text{D}_3$ .

The data in Table 1 also show that (20S)- $1\alpha$ -hydroxy- $2\beta$ -methyl-19-nor-vitamin  $\text{D}_3$  is only slightly less potent than  $1,25(\text{OH})_2\text{D}_3$  in raising calcium in the plasma calcium via the stimulation of the osteoblasts. At the same time, the activity of (20S)- $1\alpha$ -hydroxy- $2\beta$ -methyl-19-nor-vitamin  $\text{D}_3$  on intestinal calcium transport is about the same as that of  $1,25(\text{OH})_2\text{D}_3$  (Table 1). Therefore, these data show (20S)- $1\alpha$ -hydroxy- $2\beta$ -methyl-19-nor-vitamin  $\text{D}_3$  to have significant and very potent activity on bone about equal to  $1,25(\text{OH})_2\text{D}_3$ .

The compounds **Ia** and **Ib** exhibit a desired, and highly advantageous, pattern of biological activity. These compounds are characterized by relatively high intestinal calcium transport activity, as compared to that of  $1\alpha,25$ -dihydroxyvitamin  $\text{D}_3$ , while also exhibiting relatively high activity, as compared to  $1\alpha,25$ -dihydroxyvitamin  $\text{D}_3$ , in their ability to mobilize calcium from bone. Hence, these compounds are highly specific in their calcemic activity. Their activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity allows the in vivo administration of these compounds for the treatment of metabolic bone diseases where bone loss is a major concern. Because of their calcemic activity on bone, these compounds would be preferred therapeutic agents for the treatment of diseases where bone formation is desired, such as osteoporosis, especially low bone turnover osteoporosis, steroid induced osteoporosis, senile osteoporosis or postmenopausal osteoporosis, as well as osteomalacia.

(20S)-1 $\alpha$ -Hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> and (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> are much less active than 1,25(OH)<sub>2</sub>D<sub>3</sub> in binding to the vitamin D receptor (Figure 1), and they are both also only slightly less active than 1,25-(OH)<sub>2</sub>D<sub>3</sub> in causing differentiation of the promyelocyte, HL-60, into the  
5 monocyte (Figure 2). This result suggests that both (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> and (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> will be very effective in psoriasis because they have direct cellular activity in causing cell differentiation and in suppressing cell growth. It also indicates that they both will have significant activity as an anti-cancer agent, especially against leukemia,  
10 colon cancer, breast cancer and prostate cancer, as well as against skin conditions such as dry skin (lack of dermal hydration), undue skin slackness (insufficient skin firmness), insufficient sebum secretion and wrinkles. These results also illustrate that (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> and (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> are both excellent candidates for  
15 numerous human therapies and that they may be useful in a number of circumstances in addition to cancer and psoriasis such as autoimmune diseases.

Male, weanling Sprague-Dawley rats were placed on Diet 11 (0.47% Ca) diet + AEK for 11 days, followed by Diet 11 (0.02% Ca) + AEK for 31 days.  
20 Dosing (i.p.) began 7 days prior to sacrifice. Doses were given on a daily basis, 24 hours apart. The first 10 cm of the intestine was collected for gut transport studies and serum was collected for bone Ca mobilization analysis. The results are reported in Table 1.

TABLE 1

Response of Intestinal Calcium Transport and Serum Calcium (Bone Calcium Mobilization) Activity to Chronic Doses of 1,25-(OH)<sub>2</sub>D<sub>3</sub> and (20S)-1 $\alpha$ -Hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> and (20S)-1 $\alpha$ -Hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub>

Compound	Amount (pmol/day)	Ca transport S/M (mean $\pm$ SEM)	Serum Ca (mean $\pm$ SEM)
none (control)	0	4.5 $\pm$ 0.40	4.4 $\pm$ 0.07
1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub>	130	5.3 $\pm$ 0.42	5.0 $\pm$ 0.05
	260	6.5 $\pm$ 0.84	5.5 $\pm$ 0.16
(20S)-1 $\alpha$ -(OH)-2 $\alpha$ -methyl-19-nor-D <sub>3</sub>	130	8.6 $\pm$ 0.90	10.0 $\pm$ 0.20
	260	6.7 $\pm$ 0.68	12.7 $\pm$ 0.15
(20S)-1 $\alpha$ -(OH)-2 $\beta$ -methyl-19-nor-D <sub>3</sub>	130	6.8 $\pm$ 0.73	4.8 $\pm$ 0.04
	260	5.7 $\pm$ 0.45	5.1 $\pm$ 0.04

\*The above data are the average and standard error (SE) from 5 animals.

For treatment purposes, the compounds of this invention defined by formula **Ia** and **Ib** may be formulated for pharmaceutical applications as a solution in innocuous solvents, or as an emulsion, suspension or dispersion in suitable solvents or carriers, or as pills, tablets or capsules, together with solid carriers, according to conventional methods known in the art. Any such formulations may also contain other pharmaceutically-acceptable and non-toxic excipients such as stabilizers, anti-oxidants, binders, coloring agents or emulsifying or taste-modifying agents.

The compounds may be administered orally, topically, parenterally or transdermally. The compounds are advantageously administered by injection or by intravenous infusion or suitable sterile solutions, or in the form of liquid or solid doses via the alimentary canal, or in the form of creams, ointments, patches, or similar vehicles suitable for transdermal applications. Doses of from 0.01 $\mu$ g to 100 $\mu$ g per day of the compounds are appropriate for treatment purposes, such doses being adjusted according to the disease to be treated, its severity and the response of the subject as is well understood in the art. Since the compounds



exhibit specificity of action, each may be suitably administered alone, or together with graded doses of another active vitamin D compound -- e.g.  $1\alpha$ -hydroxyvitamin  $D_2$  or  $D_3$ , or  $1\alpha,25$ -dihydroxyvitamin  $D_3$  -- in situations where different degrees of bone mineral mobilization and calcium transport stimulation is  
5 found to be advantageous.

Compositions for use in the above-mentioned treatments comprise an effective amount of the (20S)- $1\alpha$ -hydroxy- $2\alpha$ -methyl-19-nor-vitamin  $D_3$  or (20S)- $1\alpha$ -hydroxy- $2\beta$ -methyl-19-nor-vitamin  $D_3$  as defined by the above formula **Ia** and **Ib** as the active ingredient, and a suitable carrier. An effective amount of such  
10 compound for use in accordance with this invention is from about  $0.01\mu\text{g}$  to about  $100\mu\text{g}$  per gm of composition, and may be administered topically, transdermally, orally or parenterally in dosages of from about  $0.01\mu\text{g/day}$  to about  $100\mu\text{g/day}$ .

The compounds may be formulated as creams, lotions, ointments, topical patches, pills, capsules or tablets, or in liquid form as solutions, emulsions,  
15 dispersions, or suspensions in pharmaceutically innocuous and acceptable solvent or oils, and such preparations may contain in addition other pharmaceutically innocuous or beneficial components, such as stabilizers, antioxidants, emulsifiers, coloring agents, binders or taste-modifying agents.

The compounds are advantageously administered in amounts sufficient to  
20 effect the differentiation of promyelocytes to normal macrophages. Dosages as described above are suitable, it being understood that the amounts given are to be adjusted in accordance with the severity of the disease, and the condition and response of the subject as is well understood in the art.

The formulations of the present invention comprise an active ingredient in  
25 association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredients. The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.

Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid  
5 or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion.

Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and carrier such as cocoa butter, or in the form of an enema.

10 Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient.


Formulations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, applicants, oil-in-water or water-in-  
15 oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops; or as sprays.

For asthma treatment, inhalation of powder, self-propelling or spray formulations, dispensed with a spray can, a nebulizer or an atomizer can be used. The formulations, when dispensed, preferably have a particle size in the range of  
20 10 to 100 $\mu$ .

The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient as a physically and chemically stable unit dose  
25 comprising either the active ingredient as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.


**THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS**

1. A compound selected from the group consisting of:  
 (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> having the formula:



or

- (20S)-1 $\alpha$ -hydroxy-2 $\beta$ -methyl-19-nor-vitamin D<sub>3</sub> having the formula:






2. A compound according to claim 1, for use in the treatment of psoriasis.
3. A compound according to claim 1, for use in the treatment of a disease chosen from leukemia, colon cancer, breast cancer and prostate cancer.
4. A compound according to claim 1, for use in the treatment of a disease chosen from multiple sclerosis, lupus, diabetes mellitus, host versus graft rejection and rejection of organ transplants.
5. A compound according to claim 1, for use in the treatment of an inflammatory disease chosen from rheumatoid arthritis, asthma and inflammatory bowel diseases.
6. A compound according to claim 1, for use in the treatment of a skin condition chosen from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration and insufficient sebum secretion.
7. A compound according to claim 1, for use in the treatment of a metabolic bone disease where it is desired to maintain or increase bone mass.
8. Use of an effective amount of a compound according to claim 1, in the preparation of a medicament for the treatment of psoriasis; a disease chosen from leukemia, colon cancer, breast cancer and prostate cancer; an autoimmune disease chosen from multiple sclerosis, lupus, diabetes mellitus, host versus graft rejection and rejection of organ transplants; an inflammatory disease chosen from rheumatoid arthritis, asthma and inflammatory bowel diseases; a skin condition chosen from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration and insufficient sebum secretion; a metabolic bone disease where it is desired to maintain or increase bone mass.
9. The use of claim 8, wherein the metabolic bone disease is selected from senile osteoporosis, postmenopausal osteoporosis, steroid-induced osteoporosis, low bone turnover osteoporosis, or osteomalacia.
10. The use according to claim 8 or claim 9 wherein the medicament is suitable for oral, parenteral, transdermal or topical administration.

11. The use according to any one of claims 8 to 10, suitable for administration in a dosage of from 0.01 µg/day to 100 µg/day.
12. A method of treating psoriasis comprising administering to a patient with psoriasis an effective amount of a compound of claim 1.
13. A method of treating a disease in chosen from leukemia, colon cancer, breast cancer and prostate cancer which comprises administering to a patient with said disease an effective amount of a compound of claim 1.
14. A method of treating an autoimmune disease chosen from multiple sclerosis, lupus, diabetes mellitus, host versus graft rejection and rejection of organ transplants which comprises administering to a patient with said disease an effective amount of a compound of claim 1.
15. A method of treatment of an inflammatory disease chosen from rheumatoid arthritis, asthma and inflammatory bowel diseases which comprises administering to a patient with said disease an effective amount of a compound of claim 1.
16. A method of treatment of a skin condition chosen from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration and insufficient sebum secretion which comprises administering to a patient with said skin condition an effective amount of a compound of claim 1.
17. A method of treatment of a metabolic bone disease where it is desired to maintain or increase bone mass which comprises administering to a patient with said disease an effective amount of a compound of claim 1.
18. The method of claim 17, wherein the disease is senile osteoporosis, postmenopausal, osteoporosis, steroid-induced osteoporosis, low bone turnover osteoporosis, or osteomalacia.
18. The method according to any one of claims 12 to 17, wherein the medicament is suitable for oral, parenteral, transdermal or topical administration.
19. The method according to any of claims 12 to 17, suitable for administration in a dosage of from 0.01 µg/day to 100 µg/day.

2003218267 15 Nov 2007

20. A compound having the formula:



**Figure 1****Figure 2**